Business
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
Highlights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test.First quarter 2026 test volume reflects 13% and 7% test volume growth year-over-year in Cancer Care Continuum and Mental Health, respectively, offset by a 12% decline year-over-year in Prenatal Health test volume.Launched Precise Molecular Residual Disease (MRD), Myriad Genetics' ultrasensitive assay, representing progress toward e
About this update from Myriad Genetics, Inc.
[{"type":"image","alt":"Myriad Genetics, Inc.","displaySize":"","headline":null,"caption":"Myriad Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/d43f1e89209f6724a2684841f43efbbf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6x2Laz667D2_wZOpyKoOpw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mw--/https://media.zenfs.com/en/globenewswire.com/d43f1e89209f6724a2684841f43efbbf","width":300,"height":138}},"lazy":false},{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test.","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"First quarter 2026 test volume reflects 13% and 7% test volume growth year-over-year in Cancer Care Continuum and Mental Health, respectively, offset by a 12% decline year-over-year in Prenatal Health test volume.","length":213,"tagName":"p"}]},{"val":[{"type":"text","content":"Launched Precise Molecular Residual Disease (MRD), Myriad Genetics' ultrasensitive assay, representing progress toward earlier insight, more informed decisions, and better outcomes for cancer patients.","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"Received FDA approval of the MyChoice CDx test as the companion diagnostic for Zejula®, for patients with advanced ovarian cancer.","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"First quarter 2026 gross margin was 68.7%, up 20.0 basis points from the first quarter 2025. ","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"First quarter 2026 GAAP net loss of $34.1 million, or $0.36 per share, while adjusted loss per share was $0.09 per share and adjusted EBITDA was $(4.5) million.","length":160,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":956,"olType":false},{"type":"text","content":"SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its first quarter ended March 31, 2026, and reaffirmed its financial guidance for the full-year 2026.","length":296,"tagName":"p"},{"type":"tex...